Replies to post #292637 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Because; the science will prevail.

You are the rare poster who only seeks to contribute scientific analysis to this message board.

Thank you.

I find no need (nor have any useful expertise) to post personal perspectives or prophecies on emerging or eventual AVXL share prices. I have no concerns with those, nor with the continuing value of my moderate AVXL holding. I've accumulated it incrementally over a number of years, always in consideration of the published science involved with blarcamesine. As a biologist cogently familiar with cellular biology I could understand both the biochemistry and cellular biology of blarcamesine, along with the possibility that the drug might have any number of obviating and disqualifying therapeutic outcomes. After all, it's treating pathologies and anomalies in the central nervous system. Few drugs acting there are both free of adverse events (side effects) and fully efficacious. Investing in startup companies targeting CNS diseases, such as Alzheimer's, Parkinson's, Rett, etc. should involve a great deal of prudent skepticism.

But, from the start, I was amazed at the murine (animal) data for transgenic CNS diseases being tested with blarcamesine. In lab rats and mice, a wide range of doses can be administered, to determine both efficacy and tolerance thresholds. Simply, the lab rats and mice dosed with blarcamesine, at virtually all dosages, responded very well; with few or minor side effects. For CNS diseases and new drugs to treat them, very rare. Profound murine validation of blarcamesine's efficacy, tolerability, and safety.

I won't go into it here, but every test in humans, in clinical trials, has produced the same positive outcomes. There're not enough of those results yet to allow the FDA to approve the drug for sales and therapeutic uses. But the utter absence of any negative therapeutic outcomes in humans bolsters my confidence in the eventual approval of blarcamesine. 'Tis but a matter of time (and the completion of the on-going clinical trials). So far, not one sentence or paragraph of negative clinical data. All (as Dr. Hagerman knows and attests to) very positive.